Antipyretics Market Patent Analysis

The global Antipyretics Market is one of the fastest developing markets that has been spreading its extensive variety of applications in the pharmaceutical industry. The number of patent applications for antipyreticsalso have beenincreasing because of headways in R &D exercises and progressions in innovating antipyretics of more kinds. The increase in R&D investment by the Government for the development of various kinds of antipyretics also encouragehigh number of patent applications for antipyretics. 

There have been an aggregate of 2,743 patent applications recorded for antipyretics,since 2015, out of which just 546 have been granted, till date. There are additionally 31 restricted and 1 revised licenses recorded during the period between 2015 and 2018. In this respect, GENENTECH INC has recorded the most astounding number of licenses that check to a figure of136 licenses, while UNIV JOHNS HOPKINS has documented the minimum number of patent applications for antipyretics that countto 32. The US has recorded 2,045 applications for antipyretics altogether from 2015 to Sept 2018. An aggregate of 1,148 patent applications were found in 2017 alone, that being the most noteworthy number of licenses recorded, since 2015. 

Browse through 149 slides and an in-depth TOC “Antipyretics Market (2019 - 2025)

GENENTECH, INC, an organization head quartered in California, USA, alone has recorded 136 patent applications for antipyretics,since 2015 and documented the highest number of patent applications in 2016, alone. Out of these 136 licenses, just 12 licenses are conceded till date. GENENTECH, INC has documented applications for antipyretics for anti-TIGIT antibodies, antipyretics for immune or inflammatory diseases and so on. The quantity of patent applications for antipyretics have increased from 2015 to 2016 and dropped in 2017. It is normal that GENENTECH, INC will document more number of licenses than 2017. 

Purdue Pharma LP, based in Stamford, USA stands second after GENENTECH, INC in documenting licenses. It has documented a sum of 85patent applications for antipyretics during the period Jan 2015-Aug 2018. Out of all licenses, 47 were conceded. It has recorded patent applications for the prevention of analgesic use, tamper resistant dosage forms, and analgesic antipyretic drugs and so on. The quantity of patent applications for antipyretics have expanded from 2015 to 2016 and dropped down in 2017. So, it is expected that Purdue PharmaLP will document more number of licenses than 2016, when 30 licenses applications records were found. 

Covidien LP, an organization based in Dublin, Ireland stands third in documenting licenses, after GENENTECH Inc. andPurduePharma. It has documented a sum of 67 licenses for antipyretics,out of which 50 were allowed, till date. The licenses incorporate antipyretics or analgesic use, antipyretics for spot temperature reduction and so on, since 2015. There have been fluctuationsin thenumber ofpatent applications by CovidienLP during the period 2015-2017 and it is focusing to achieve a more prominent number in 2018. 

The highest number of patent applications were recorded in the US, thatrounds to a number of 2,045 whereas there are just 11 patent application recorded in Europe for antipyretics since 2015. The increasing requirements for antipyretics in the pharmaceuticals industry is the major factor that is favoring the growth number of patent applications. 

Hence, it can be said that the significant players such as GENETECH INC, Purdue Pharma LP, and Covidien LP will file more number of patent application for its innovation in antipyretics. All these patent applications are further checked by the United States Patent and Trademark Office for its endorsement rights. All the above mentioned patents for antipyretics are expected to commercialize by 2018 after their approval by the United States and Trademark office. A total of 2,197 patents were rejected by the same for not meeting the needs of specifications required for patent applications.

Talk to one of our sales representative about the full report by providing your details in the below link:

Related Reports:

Acne Vulgaris Market: By Treatment (Adapalene, Tazaroteen, Tretinoin & Isotretinoin, Erythromycin & Clindamycin, Hormonal Agents, Anti-inflammatory, Azelaic acid, Resorcinol, Laser & Light Therapy, Cosmetic Procedures & Acne Scar Treatment); By Device (Laser & Heat Extraction devices); By Geography - Forecast(2018-2023)

Infection prevention & Control Market: By Infections (Microbial & Others); By Antimicrobial Drugs (Antibacterial & Others); By Accessories & Equipment (Disinfectants & Others); By End User (Equipment & Drug Usage) & By Geography - Forecast (2018-2023)

About IndustryARC:

IndustryARC is a research and consulting firm that publishes more than 500 reports annually in various industries, such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food & Beverages, Information Technology, Life sciences & Healthcare.

IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications of the Market. Our Custom Research Services are designed to provide insights into the constant flux in the global demand-supply gap of markets. Our strong analyst team enables us to meet the client research needs at a very quick speed with a variety of options for your business.

We look forward to supporting the client to be able to better address customer needs; stay ahead in the market; become the top competitor and get real-time recommendations on business strategies and deals. Contact us to find out how we can help you today.

Contact Us:
Mr. Venkateshwar Reddy
Business Development Manager 
Contact Sales: 1-614-588-8538 (Ext-101)
Connect with us on LinkedIn -